Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase myopathy is less common in children but has been associated with more favorable prognosis than adult patients after immunotherapies. We report anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibody positivity in a 6-year-old boy with progressive muscle weakness, scoliosis, spinal rigidity, multiple joint contractures, mild left ventricular hypertrophy, and elevated serum creatine kinase. In contrast to most of previously reported pediatric anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase myopathy, he showed little response to immunotherapies. Muscle biopsy contained changes suggestive of myofiber necrosis and regeneration and reducing bodies. The diagnosis of reducing body myopathy was later confirmed by reported c.368A>G (p.His123Arg) mutation in the FHL1 gene. Although the level of association between these two conditions is still inconclusive, this is the first report of concurrent positive anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibody with reducing body myopathy emphasizing the possibility of co-occurrence of immune mediated necrotizing myopathy and muscular dystrophy and importance of comprehensive diagnostic investigations in unusual cases.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nmd.2019.05.007DOI Listing

Publication Analysis

Top Keywords

anti-3-hydroxy-3-methylglutaryl-coenzyme reductase
20
reductase antibody
12
reducing body
12
body myopathy
12
concurrent positive
8
positive anti-3-hydroxy-3-methylglutaryl-coenzyme
8
antibody reducing
8
reductase myopathy
8
myopathy
6
anti-3-hydroxy-3-methylglutaryl-coenzyme
5

Similar Publications

Statin-Induced Necrotizing Autoimmune Myopathy: Diagnosis and Treatment Approach.

JCEM Case Rep

December 2024

Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN 55905, USA.

The widespread use of statins for cardiovascular diseases has unveiled a new subset of inflammatory myopathy, immune-mediated necrotizing myopathy (IMNM). We describe below an unusual case of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) myopathy. A 64-year-old male individual with type 2 diabetes, hyperlipidemia, and coronary artery disease presented with progressive proximal muscle weakness and pain for 3 months.

View Article and Find Full Text PDF

[Not Available].

Ugeskr Laeger

October 2024

Afdeling for Hjertesygdomme, Sygehus Sønderjylland, Aabenraa.

Statin-induced immune-mediated necrotising myopathy (IMNM) is a rare complication associated with statin use. IMNM is classified as one of the inflammatory myopathies characterised by myalgia and elevated serum creatine kinase (CK) levels. In this case report, we present a 58-year-old woman who developed IMNM secondary to atorvastatin use.

View Article and Find Full Text PDF

Statins, commonly used for hyperlipidemia and more importantly having proven efficacy in lowering cardiovascular risk, are a very popular class of medications. Side effects are usually mild, and the class as a whole is generally well-tolerated by patients. However, one rare and more serious side effect is statin-induced autoimmune necrotizing myopathy.

View Article and Find Full Text PDF
Article Synopsis
  • Anti-HMGCR-positive immune-mediated necrotising myopathy (IMNM) is linked to IgG autoantibodies against HMGCR and specific HLA-DR alleles, but HMGCR-specific CD4T-cells had not been previously identified in affected patients.
  • This study demonstrated that patients with anti-HMGCR+IMNM show heightened CD4T-cell responses to HMGCR compared to those with dermatomyositis, with a significant correlation between these responses and the levels of anti-HMGCR antibodies.
  • The presence of distinct HMGCR-reactive CD4T-cells in both blood and muscle tissues highlights their potential role in the disease's development.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!